Watch VERA. Know when insiders buy.
One email the day a filing lands. Free.
VERA
Vera Therapeutics, Inc.
31.20
+1.14 +3.79%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
19
FLAG · insiders 25, shorts 12
Insiders, 90 days
−$1.3M
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.2BP/E —DIV YIELD —FCF YIELD -15.07%REV TTM —NET INCOME −$401.9MNET DEBT $26.4M52W 24.10 – 55.67SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$112.5M | −$109.5M | — | -1.52 | −$100.3M | $0 | −$100.3M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$125.1M | −$121M | — | -1.69 | −$106.5M | $23K | −$106.5M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$94.2M | −$91.1M | — | -1.39 | −$70M | $102K | −$70.1M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$83.9M | −$80.3M | — | -1.26 | −$61.9M | $133K | −$62M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$80.1M | −$76.5M | — | -1.20 | −$54.8M | $208K | −$55M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$57.2M | −$51.7M | — | -0.81 | −$54.4M | $187K | −$54.6M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$48.9M | −$43.4M | — | -0.72 | −$39.2M | $645K | −$39.8M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$49.8M | −$46.6M | — | -0.85 | −$36.9M | $238K | −$37.1M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$37.3M | −$33.7M | — | -0.62 | −$24.8M | $89K | −$24.9M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$31.1M | −$28.4M | — | -0.56 | −$33.8M | $0 | −$33.8M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$27M | −$25.7M | — | -0.58 | −$25.1M | $63K | −$25.2M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$21.8M | −$20.1M | — | -0.45 | −$23M | $0 | −$23M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$315.5M | −$299.6M | — | -4.66 | −$241.1M | $630K | −$241.7M | $0 | — |
| FY2024 · to Dec 31 | — | — | −$167.2M | −$152.1M | — | -2.75 | −$134.7M | $972K | −$135.7M | $13K | — |
| FY2023 · to Dec 31 | — | — | −$102M | −$96M | — | -2.25 | −$92.2M | $63K | −$92.2M | $0 | — |
| FY2022 · to Dec 31 | — | — | −$90.9M | −$89.1M | — | -3.35 | −$67.6M | $62K | −$67.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$34.4M | −$32.6M | — | -2.43 | −$23.7M | $0 | −$23.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$52.2M | −$53.4M | — | -166.93 | −$34.8M | $99K | −$34.9M | — | — |
Every number comes from Vera Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.